ONCOLYTICS BIOTECH INC — Form 8-K
Filed July 24, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
On July 20, 2026, Oncolytics Biotech received a notice of delisting or failure to satisfy continued listing standards from its exchange. The 8-K filed July 24, 2026 discloses Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing), but the filing provides no details on the specific rule violated, timeline for cure, or remediation plan. No counterparties, dollar amounts, or concrete remediation details are disclosed in the available filing text.
Why this rating
Delisting notice is a major threat to a $72M biotech; threatens capital access and viability. Severity unclear—depends on cure period and reason—but exchange warning is serious for small-cap.
Extracted items
See more from July 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.